Trial Profile
ONO-7847 Phase 3 Study, A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy and Safety of ONO-7847 for the Prevention of Cancer Chemotherapy-Induced Nausea and Vomiting in Patients with Malignant Tumor.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 May 2016
Price :
$35
*
At a glance
- Drugs Fosaprepitant (Primary) ; Dexamethasone; Granisetron
- Indications Chemotherapy-induced nausea and vomiting
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Ono Pharmaceutical
- 11 Dec 2012 New trial record
- 31 Oct 2012 Results published in the Annals of Oncology.